Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
47.9M
-
Shares change
-
-13.7M
-
Total reported value, excl. options
-
$260M
-
Value change
-
-$112M
-
Put/Call ratio
-
2.28
-
Number of buys
-
61
-
Number of sells
-
-40
-
Price
-
$5.45
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2021
124 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q2 2021.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.9M shares
.
Largest 10 shareholders include FMR LLC (9.05M shares), Bain Capital Life Sciences Investors, LLC (5.79M shares), BlackRock Inc. (4.46M shares), Ally Bridge Group (NY) LLC (3.44M shares), VANGUARD GROUP INC (2.78M shares), Omega Fund Management, LLC (2.27M shares), Samsara BioCapital, LLC (2.19M shares), ORBIMED ADVISORS LLC (1.84M shares), Artal Group S.A. (1.7M shares), and Altium Capital Management LP (1.08M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.